[go: up one dir, main page]

WO2006005583A3 - Especes de polypeptides secretes impliques dans la sclerose en plaques - Google Patents

Especes de polypeptides secretes impliques dans la sclerose en plaques Download PDF

Info

Publication number
WO2006005583A3
WO2006005583A3 PCT/EP2005/007561 EP2005007561W WO2006005583A3 WO 2006005583 A3 WO2006005583 A3 WO 2006005583A3 EP 2005007561 W EP2005007561 W EP 2005007561W WO 2006005583 A3 WO2006005583 A3 WO 2006005583A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
secreted polypeptide
species involved
polypeptide species
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007561
Other languages
English (en)
Other versions
WO2006005583A2 (fr
Inventor
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneprot Inc
Original Assignee
Geneprot Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneprot Inc filed Critical Geneprot Inc
Publication of WO2006005583A2 publication Critical patent/WO2006005583A2/fr
Publication of WO2006005583A3 publication Critical patent/WO2006005583A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides sécrétés humains dont la concentration est spécifiquement modifiée dans le sérum provenant d'individus souffrant de la sclérose en plaques par rapport au sérum provenant d'individus ne souffrant pas de la sclérose en plaques. L'invention concerne également des méthodes d'utilisation de ces compositions comprenant lesdits polypeptides, des polynucléotides codant pour ces polypeptides et des anticorps spécifiques de ceux-ci permettant de diagnostiquer et de pronostiquer une sclérose en plaques et de développer un médicament.
PCT/EP2005/007561 2004-07-12 2005-07-12 Especes de polypeptides secretes impliques dans la sclerose en plaques Ceased WO2006005583A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58724904P 2004-07-12 2004-07-12
US60/587,249 2004-07-12

Publications (2)

Publication Number Publication Date
WO2006005583A2 WO2006005583A2 (fr) 2006-01-19
WO2006005583A3 true WO2006005583A3 (fr) 2006-07-13

Family

ID=35614590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007561 Ceased WO2006005583A2 (fr) 2004-07-12 2005-07-12 Especes de polypeptides secretes impliques dans la sclerose en plaques

Country Status (1)

Country Link
WO (1) WO2006005583A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7123684B2 (en) 2002-11-27 2006-10-17 Hologic, Inc. Full field mammography with tissue exposure control, tomosynthesis, and dynamic field of view processing
US20100062472A1 (en) * 2006-05-26 2010-03-11 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2008134577A1 (fr) 2007-04-25 2008-11-06 Reed Guy L Procédé d'augmentation de l'activité de la plasmine par conversion en antiplasmine
WO2010005387A1 (fr) * 2008-07-10 2010-01-14 Astrazeneca Ab Procédé et marqueurs inédits pour le diagnostic de la sclérose en plaques
WO2010049103A1 (fr) * 2008-10-31 2010-05-06 Eth Zurich Protéines apom tronquées solubles et leurs utilisations médicales
KR101320633B1 (ko) * 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
AU2012304635B2 (en) 2011-09-06 2017-08-31 Translational Sciences Inc. SerpinF2-binding molecules and methods of use
WO2016106186A1 (fr) 2014-12-22 2016-06-30 Translational Sciences, Inc. Prophylaxie de la thrombose
CN118767135A (zh) * 2023-04-10 2024-10-15 复旦大学 治疗皮肤纤维化的药物及方法
WO2025101643A1 (fr) * 2023-11-06 2025-05-15 Mayo Foundation For Medical Education And Research Évaluation et traitement de la sclérose en plaques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059604A2 (fr) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059604A2 (fr) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ 1 July 2004 (2004-07-01), "Human NOVX polypeptide #90", XP002365253, retrieved from EBI Database accession no. ADM93548 *
DATABASE GENESEQ 16 January 2002 (2002-01-16), "Human breast cancer-associated protein isoform, BPI-248 peptide #1", XP002365442, retrieved from EBI Database accession no. AAU68420 *
DATABASE GENESEQ 16 January 2002 (2002-01-16), "Human breast cancer-associated protein isoform, BPI-248 peptide #2", XP002365443, retrieved from EBI Database accession no. AAU68421 *
DATABASE GENESEQ 3 June 2004 (2004-06-03), "Human angiogenesis-related transgelin 2 (TAGLN2) protein", XP002365254, retrieved from EBI Database accession no. ADL35877 *
FANGERAU T ET AL: "Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria", ACTA NEUROLOGICA SCANDINAVICA, vol. 109, no. 6, June 2004 (2004-06-01), pages 385 - 389, XP002365251, ISSN: 0001-6314 *

Also Published As

Publication number Publication date
WO2006005583A2 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2007092640A3 (fr) Anticorps qui se lient à par-2
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EP1603949B8 (fr) Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
WO2004075861A3 (fr) Production de virus recombines adeno associes
WO2002083070A3 (fr) Composes pour l'ummunotherapie et le diagnostic du cancer du colon et methodes d'utilisation associees
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
WO2005052000A3 (fr) Anticorps et partenaires de liaison anti-il 20 et procedes d'utilisation dans l'inflammation
GEP20115226B (en) P-cadherin antibodies
WO2006007853A3 (fr) Procedure de caracterisation structurelle d'une proteine polyclonale recombinee ou d'une lignee de cellules polyclonales
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
WO2009028880A3 (fr) Composition de marqueur biologique pour la détection de la rétinopathie diabétique et nécessaire de diagnostic à cet effet
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2006005583A3 (fr) Especes de polypeptides secretes impliques dans la sclerose en plaques
WO2005028497A3 (fr) Peptides se liant a des recepteurs derives de proteines sars s
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
WO2005015206A3 (fr) Espece de polypeptides secretes associee aux troubles cardiovasculaires
WO2005000876A3 (fr) Proteines de la famille des proteines a doigts de zinc (ring finger) et leurs utilisations
WO2008142664A3 (fr) Peptides exposés associés à la prolifération, ligands et procédés mettant en œuvre de tels peptides
WO2006069765A3 (fr) Especes de polypeptides secretes impliquees dans la sclerose en plaques
CA3248965A1 (fr) Anticorps anti-b7-h7 ou fragment de liaison à l'antigène de celui-ci, son procédé de préparation et son utilisation
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2006029838A3 (fr) Especes polypeptidiques secretees impliquees dans la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase